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Abstract
Background
Artemether-lumefantrine (AL) was introduced for treatment of uncomplicatedmalaria in
Guinea-Bissau in 2008. Malaria then resurged and recurrentmalaria after treatmentwith AL
and stock-outs of AL were common. This study therefore aimed to assess the efficacy of AL
and identify an alternative second line antimalarial. Dihydroartemisinin-piperaquine (DP)
was chosen as it has been shown to be safe and efficacious and to reduce the incidence of
recurrentmalaria.
Methodsand Findings
In a multicentre randomised open-label non-inferiority clinical trial, AL or DP were given
over 3 days to children aged 6 months-15 years with uncomplicatedP. falciparummono-
infection. Intake was observed and AL was given with milk. Children were seen on days 0,
1, 2 and 3 and then weekly days 7–42. RecurringP. falciparumwere classified as recrudes-
cence or new infections by genotyping. Between November 2012 and July 2015, 312 chil-
dren were randomised to AL (n = 155) or DP (n = 157). The day 42 PCR adjusted per
protocol adequate clinical and parasitological responses were 95% and 100% in the AL and
DP groups respectively, Mantel-Haenszel weighted odds ratio (OR) 0.22 (95%CI 0–0.68),
p = 0.022. In a modified intention to treat analysis in which treatment failures day 0 and
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reinfections were also considered as treatment failures adequate clinical and parasitological
responses were 94% and 97% (OR 0.42 [95%CI, 0.13–1.38], p = 0.15). Parasite clearance
and symptom resolution were similar with both treatments.
Conclusions
Both treatments achieved theWHO recommended efficacy for antimalarials about to be
adopted as policy. DP was not inferior to AL for treatment of uncomplicatedP. falciparum
malaria in Guinea-Bissau.
Trial Registration
ClinicalTrials.gov NTC01704508
Introduction
Plasmodium falciparum causes malaria and approximately 580 000 deaths each year [1]. Due
to widespread resistance to antimalarial monotherapies, theWorld Health Organization rec-
ommends artemisinin-based combination therapy (ACT) for treatment of uncomplicated P.
falciparum malaria. Artemether-lumefantrine (AL), dihydroartemisnin-piperaquine (DP) and
artesunate-amodiaquine are the ACTs of primary relevance for use in Africa [2].
When AL was introduced for treatment of uncomplicated malaria in Guinea-Bissau in
2008, its efficacywas 97% [3]. Despite this, malaria resurged between 2008 and 2012 [4]. Data
suggests that this increase was due to poorer than expected effectiveness of AL (unpublished
data), unavailability of AL due to stock-outs and to increased use of the second-line drug qui-
nine [4]. Quinine is typically given for 3 instead of 7 days in Guinea-Bissau and has very poor
efficacywhen used in that way [5]. Guinea-Bissau needs an alternative ACT for use when AL is
not available or fails. Furthermore, concurrent use of multiple first line therapies may delay the
development of drug resistance [6].
DP is taken once daily and has been shown to be safe, well tolerated and highly efficacious
(>95%) in several African settings [7–10]. DP also protects from re-infection for longer time
than AL and has thereby been linked to reduced incidence of uncomplicated and complicated
malaria infections as well as hospitalizations in high transmission settings [8, 11]. DP has how-
ever, never been used in Guinea-Bissau. Artesunate-amodiaquine is also a potential ACT for
use in Guinea-Bissau. However, amodiaquine tolerant P. falciparum exist in the country and
the incidence has increased in recent years [12, 13]. We therefore conducted this non-inferior-
ity randomised clinical trial to determine the efficacy and safety of AL and DP for the treatment
of uncomplicated P. falciparum malaria in Guinea-Bissau.
Methods
Ethics and registration
The study was conducted in accordance with the Declaration of Helsinki and GoodClinical
Practice.Written informed consent was obtained from all parents/legal guardians. The Minis-
tério da Saúde Pública in Guinea-Bissau (Ref (2)/CNES/INASA/2012 and ref 011/CNES/
INASA/2013) gave ethical approval. The regional ethics committee in Stockholm, Sweden
approved the molecular analyses (2011/832-32/2). The study was registered at ClinicalTrials.
gov (NCT01704508).
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Study site and period
The BandimHealth and Demographic Surveillance Site (HDSS) was established in 1978 and
covers a 16 km2 area of suburban Bissau, the capital of Guinea-Bissau [14]. Three health cen-
tres and the national hospital approximately 4 km away serve the population. The study was
conducted at The Bandim and BelemHealth Centres. Each centre has a small laboratory
manned by trained laboratory technicians equipped with microscopes and rapid diagnostic
tests for malaria. Nurses routinely see paediatric patients in the mornings and as emergencies
during afternoons and weekends.
P. falciparum was mesoendemic during the 1990’s and then gradually decreased reaching
the lowest recorded incidence in 2007. Malaria resurged between 2008 and 2012. Following
mass distribution of insecticide treated bed-nets in November 2011 the malaria incidence
decreased again [4]. Malaria transmission is now very seasonal with a peak in November and
minimal transmission February-July. This study was conducted betweenNovember 2012 and
July 2015 covering 2.5 transmission seasons.
Patients
Inclusion criteria were: Mono-infection with P. falciparum without signs of severe malaria or
danger signs. Parasite density of 800–200 000 trophozoites/μL, axillary temperature>37.5°C
or a history of fever during the previous 24 hours, age 6 months to 15 years, haemoglobin
>50g/L, no other significant illness, no reported intake of antimalarials during the past week
and residence within the study area.
Study design
This was a multicentre, randomised open-label non-inferiority clinical trial comparing DP
with AL for the treatment of children with uncomplicated malaria. Randomisation was
achieved by mothers drawing a sealed card with either Eurartesim or Coartemwritten on it
from an envelope containing 10 of each card. Study nurses allocated treatment according to the
drawn card. Cards and envelopes were prepared by the investigators.
Medication was given and supervisedby an experiencednurse. Tablets were crushed for
young children unable to swallow them whole. Mothers were encouraged to continue nursing.
AL was given with approximately 200 mL of milk.
AL containing 20 mg of artemether and 120 mg of lumefantrine (Ipca LaboratoriesTM,
Mumbai, India) were purchased from the national drug dispensary (CECOM). 1–4 tablets per
dose were prescribed according to body weight and given at approximately 0, 8, 24, 36, 48, and
60 hours after inclusion.
DP tablets containing 20/160 mg or 40/320 mg dihydroartemisinin/piperaquine (Eurarte-
sim1) were provided free of charge by Sigma-Tau, Rome, Italy. DP was dosed according to
body weight once daily on days 0, 1 and 2. The daily number of tablets of Eurartesim1 20/160
mg were 0.5 (5 to<7kg) or 1 (7 to<13kg). The daily number of tablets of Eurartesim 40/320
mg were 1 (13 to<24kg), 2 (24 to<36) or 3 (36 to<75kg).
Doses were repeated to children vomiting within 30 min of treatment. If a child vomited
again during the next 30 min, the child was given quinine intramuscularly and withdrawn.
Concomitantly prescribed drugs were administered and recorded. P. falciparum detected after
day 7 were treated with AL.
Children were seen twice daily on days 0, 1 and 2 and then once on days 3, 7, 14, 21, 28, 35
and 42. Clinical condition was assessed, temperature measured and mothers were questioned
about their child’s general condition and the occurrence of fever, any symptoms, hospital
admission or intake of any drugs each time a child was seen. Daily on days 0, 1, 2, 3 and 7,
AL versus DP for Treatment of Malaria in Guinea-Bissau
PLOSONE | DOI:10.1371/journal.pone.0161495 September 20, 2016 3 / 11
patients and / or their care-giver were asked if the patient had any of the following symptoms
during the past 24 hours: Fever, convulsions, joint pains, diarrhoea, stomach pain, itch, rash,
palpitations, inability to eat, sleep and drink, their general condition and any other symptoms.
Symptoms were graded as not present, moderate or severe. In addition, the attending nurse
assessed patient’s general condition as well, ill or very ill and measured the temperature. If a
child was not seen during a weekly visit, a health worker phoned the parent/guardian or revis-
ited the house the following two days. Children were given free medication and were encour-
aged to return at any time if their health deteriorated. If a child was admitted to hospital, the
diagnosis and treatment was recorded. Each time a child was seen, including unscheduled visits
to the health centres, Giemsa stained thick and thin smears were made to identify and quantify
any malaria parasites. Bloodwas put on to filter-paper (Whatman 3MM) for later genotyping
whenever a slide was made except for days 1 and 2 and when no parasites were found during
unscheduled visits. Filter-papers were put into separate sealed plastic bags to avoid contamina-
tion and stored with a desiccant (Minipax1, Sigma-Aldrich1).
Laboratorymethods
Children with symptoms suggestive of malaria were screened using rapid diagnostic tests (First
Response1) and Giemsa stained thick and thin smears using finger prick blood. Species were
identified and asexual parasite density quantified (per 200 white blood cells) using 1000 times
magnification and a sunlit microscope. A slide was considered negative after examination of
100 high power fields.
Haemoglobin was measured using a HaemoCue (Ängelholm, Sweden) on days 0, 3 and 42.
Moderate anaemia was defined as haemoglobin<100 g/l in children under 5 years of age and
<110 g/l in older children. For severe anaemia the corresponding haemoglobin values were 70
and 80 g/l, respectively.
DNA was extracted from two 3 mm punches of blood soaked filter-paper using a chee-
lexTM based extractionmethod. DNA was frozen in aliquots at –20°C until amplification by
PCR. New and recrudescent infections were distinguished using a nested PCR protocol
according to WHO recommendations [15]. Merozoite surface proteins 1 and 2 and P falcipa-
rum glutamate rich protein were analysed in matching day 0 samples and day of recurring P.
falciparum. PCR products were resolved on agarose gels (Amresco, Solon, OH), stained with
ethidium bromide and visualized under UV transillumination (GelDoc1, Biorad, Hercules,
Ca, USA).
Treatment outcomes
We used theWHO criteria to identify early treatment failures (ETF), late clinical failures
(LCF), late parasitological failures (LPF) and adequate clinical and parasitological response
(ACPR) [16]. Briefly, ETF was defined as the development of danger signs or severe malaria on
days 1–3 in the presence of parasitaemia. PCR verified recrudescenceof P. falciparum between
days 7–42 was defined as LCF if the subject had symptoms of malaria and LPF if there were no
symptoms. In the per protocol analysis ETF and PCR corrected LCF and LPF were considered
as treatment failures whereas reinfections (identified by PCR genotyping) were censored. In
the intention to treat analysis day 0 treatment failures, ETF and all reparasitaemias were con-
sidered as treatment failures. Patients were censored due to loss to follow up if they had moved
from the study area or were not seen on two consecutive weekly visits. Patients were censored
due to withdrawal of consent if they refused blood sampling for malaria diagnosis at any time
during the study period.
AL versus DP for Treatment of Malaria in Guinea-Bissau
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The primary endpoint was PCR adjusted per protocol ACPR day 42. Secondary endpoints
included intention to treat ACPR day 42, haemoglobin recovery, fever and parasite clearance
and drug tolerability.
Statistics
Assuming a PCR corrected per protocol day 42 ACPR of 97% (based on data from a trial with
AL in 2008), 5% significance level (alpha), 80% power (1-beta), a non-inferiority limit (d) of
5% the sample size was calculated to be 288 not accounting for loss to follow up. Sample sizes
were calculated to be 317 and 346 assuming a 10% and 20% loss to follow up, respectively.
Data analysis was done using Stata 12.0 and Epi Info™. We planned to compare treatment
arms using a Cox proportional hazards model but this was not possible as the efficacy of DP
was 100% in the per protocol analyses. Treatment outcomes were therefore compared using
Mantel-Haenszel weighted odds ratio (OR). Nevertheless, the effect of sex, age group (<5, 5–9
and 10–14 years), parasite density (<50000, 50000–99999 and>99999 P. falciparum/μL) and
study site were assessed in the intention to treat analysis using a Cox proportional hazards
model. No predictor had a significant effect. Data from the Mantel-Haenszel analysis only are
therefore presented. Quantile regressions with bootstrapping (100 repetitions) were used to
compare parasite densities, body temperatures and haemoglobin values. Quantile regressions
were used as parasite density was not normally distributed and because we wished to analyse
medians to minimise the effect of outliers. Symptoms, the proportion of children with anaemia,
the proportion of children with parasitaemia and gametocytes on specific days were analysed
using Fisher’s exact test.
Results
A total of 8338 children were screened for malaria of which 494 were found to have P. falcipa-
rum on examination of thick and thin smears. Inclusion criteria were not fulfilledby 182 chil-
dren due to residence outside the study area (primarily), low parasite density or unwillingness
to participate. The study was stopped when 312 children had been included because a new
study was due to start. Participant flow is shown in Fig 1. All withdrawals of consent were due
to parents/guardians not wanting more blood sampling to be done. In the AL and DP arms
loss to follow up by day 42 was 10% (n = 15) and 8% (n = 12), respectively. Losses to follow up
were due to children travelling. Baseline characteristics (Table 1) were similar between groups
even when stratified into age groups except for gender. Gender was not associated with severity
of disease, other symptoms or parasite density.
Treatment outcomes are shown in Table 2. The PCR adjusted per protocol day 42 ACPRs
were 95% (95% confidence interval [CI], 91–98%) and 100% (CI could not be calculated) for
AL and DP respectively. In numbers this was 7 versus 0 treatment failures and 128 versus 136
ACPRs in the AL and DP arms, respectively. DP was significantly less likely to result in treat-
ment failure OR 0.22, (95% CI, 0–0.68, p = 0.022). The non-inferioritymargin was 90% and
this was most probably achieved but as 95% confidence intervals could not be calculated non-
inferiority was in a strict sense not shown. In the modified intention to treat analysis in which
treatment failures on day 0 and all recurrent infections were considered as treatment failures
the ACPRs were 94% (95% CI, 89–97%) and 97% (95% CI, 93–99%) for AL and DP, respec-
tively (OR 0.43, [95% CI, 0.10–1.56], p = 0.15). The non-inferioritymargin was 89% in this
analysis and as DPs lower 95% CI was 93% DP was non-inferior and not superior.
There were two treatment failures (considered as ETF in the intention to treat analysis) on
day 0 in both the AL and DP arms and four ETF on day one in the AL arm. All eight ETF were
admitted to hospital (six to the national hospital, one to the Bandim health centre and one to a
AL versus DP for Treatment of Malaria in Guinea-Bissau
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different hospital). The number of ETF were not significantly different between treatment
arms (Fishers exact p = 0.17). No other children received antimalarial treatment outside of the
study protocol.
There were three recrudescent infections in the AL arm occurringon day 14 (n = 2) and 21
and none in the DP arm. There were two new infections (day 35 and day 42) in the DP arm
and none in the AL arm
Median haemoglobin values decreased significantly between day 0 and day 3 and increased
significantly between day 3 and day 42 in both treatment arms (p<0.001) as shown in Table 3.
The proportion of children with moderate (p<0.01) and severe (p<0.02) anaemia changed
Fig 1. Patient Flow. All withdrawals of consent were due to patients not wantingmore blood samples to be taken. All losses to follow up were due to patients
travelling. Patients that travelled or withdrew consent contributed time to the Mantel-Haenszel weighted odds ratio calculation until they were censored.
doi:10.1371/journal.pone.0161495.g001
AL versus DP for Treatment of Malaria in Guinea-Bissau
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similarly. Median haemoglobin values and the proportion of children with moderate or severe
anaemia did not differ significantly between treatment groups.
Median parasite densities were 18800 (95% CI, 8710–28890) and 23121 (95% CI, 15577–
30666) P. falciparum/μl on day 0 in the AL and DP groups, respectively. These decreased to
1280 (95% CI, 846–1714) and 480 (95% CI 332–628) P. falciparum/μl on day 1 (p<0.001). The
proportion of children with parasitaemia on days 0, 1, 2 and 3 and rate of fever clearance were
not significantly different between treatment arms. Stratifying by age did not affect this.
Table 1. Basic characteristics at inclusion.
Characteristic Artemether-lumefantrine Dihydroartemisinin-piperaquine
Median age (years) 10 (7–12) 10 (7–12)
Weight (Kg) 27 (20–34) 27 (20–35)
Sex (male:female) 91:64 63:94
P. falciparum / μL 18800 (7600–47619) 23121 (11400–57971)
Axillary temperature °C 38.1 (37–39.1) 38.3 (37–39.2)
Haemoglobin (g/dL) 112 (100–123) 113 (102–122)
Moderate or severe anaemia 37% 37%
Assessed clinical condition
Very ill 29 (19%) 32 (21%)
Moderately ill 124 (80%) 120 (78%)
Not ill 1 (1%) 2 (1%)
Interquartile ranges are shown in brackets
Moderate anaemiawas defined as haemoglobin <100 g/l in children under 5 years of age and <110 g/l in older children. For severe anaemia the
corresponding haemoglobin values were 70 and 80 g/l, respectively.
The attending nurse assessed patient’s general condition as well, ill or very ill.
doi:10.1371/journal.pone.0161495.t001
Table 2. Treatment outcome.
Artemether-lumefantrine Dihydroartemisinin-piperaquine Weighted odds ratio
Number 155 157
ACPR 128 136
Per protocol ACPR 95% 100% 0.22 (95%CI 0–0.68)*, p = 0.022
Early treatment failure 4 0
Late clinical failure 3 0
Modified intention to treat ACPR 94% 97% 0.43 (95%CI, 0.10–1.56), p = 0.15
Early treatment failure 6 2
Late clinical failure 3 0
New infection 0 2
Withdrawal of consent 3 5
Lost to follow up 15 12
ACPR Adequate clinical and parasitological response
*There were two treatment failures in both the DP and AL group on day 0 that were treated as wrong inclusions in the per protocol analysis.
In the modified intention to treat analysis treatment failures on day 0 and new infections were considered as treatment failures. Withdrawal of consent and
loss to follow up were censored in the per protocol and intention to treat analyses.
doi:10.1371/journal.pone.0161495.t002
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Gametocyte carriage was less than 1% in both treatment arms throughout the study and did
not vary significantly with treatment. No gametocytes were seen on days 35 and 42.
Symptom resolution and adverse events
On days 0, 1, 2 and 3, the proportion of patients assessed by the study nurse as ill or very ill
were 99%, 70%, 17% and 2% in the AL arm and 99%, 60%, 14% and 3% in the DP arm. On day
0, 1, 2 and 3 convulsions, joint pains, diarrhoea, stomach pain, itch, rash, palpitations, inability
to eat, sleep and drink and/or any other symptoms during the past 24 hours were reported in
42%, 18%, 5% and 1% in the AL arm and 40%, 15% 3% and 1% in the DP arm. There were no
significant differences. Except for recurrent parasitaemia, there were no severe adverse events
during the follow up.
Treatment was repeated due to vomiting on day 0 in 4/155 and 7/157 children receiving AL
and DP, respectively (p = 0.54). On days 1 and 2 treatment was repeated in one and zero chil-
dren taking AL and one and two children taking DP, respectively.
Discussion
This aim of this study was to assess and compare the efficacy of AL and DP in Bissau, Guinea-
Bissau. The study was prompted by a perceived lack of effectiveness of AL whenmalaria
resurged between 2008 and 2012 and a wish to identify a second line ACT [4]. The95% PCR
corrected efficacyof AL and DP allays fears of widespread AL resistance and shows that DP ful-
filledWHO criteria for antimalarials to be introduced [2]. Furthermore, DP was shown to be
non-inferior and not superior to AL in the non-inferiority analysis. Thus both AL and DP can
be recommended for the treatment of uncomplicated malaria in Guinea-Bissau.
The per protocol day 42 PCR corrected efficacyof DP (100%) was significantly better than
that of AL (95%). There were four ETFs and three LCFs in the AL arm versus none in the DP
arm. Furthermore, the median parasite density was significantly higher in the AL arm (1280
Pf/μl) compared to the DP arm (480 Pf/μl) on day one. On the other hand, the majority of chil-
dren cleared P. falciparum within 48 hours of starting treatment with AL or DP suggesting that
Table 3. Medianhaemoglobin values (g/L) and proportionof childrenwith anaemia on days 0, 3 and 42.
Artemether-lumefantrine Dihydroartemisinin-piperaquine All
Day 0 Median Hb (95%CI)) 112 (107–117) 113 (110–1116) 113 (110–116)
Moderate anaemia 36% 36% 36%
Severe anemia 1% 1% 1%
Day 3 Median Hb (95%CI) 106 (102–110) p = 0.08 106 (104–109) p = 0.001 106 (104–108) p<0.001
Moderate anaemia 53% 56% 55%
Severe anaemia 10% 7% 8%
Day 42 Median Hb (95%CI) 117 (115–120) p<0.001 118 (115–121) p<0.001 118 (116–120) p<0.001
Moderate anaemia 23% 23% 23%
Severe anaemia 0% 1% 0.4%
Moderate anaemiawas defined as haemoglobin <100 g/l in children under 5 years of age and <110 g/L in older children. For severe anaemia the
corresponding haemoglobin values were 70 and 80 g/L, respectively.
Median haemoglobin values and 95% confidence intervals were calculated and compared using quantile regression. Proportions were compared using
Fishers exact test.
Median haemoglobin decreased significantly between day 0 and day 3 and increased significantly between day 3 and day 42 in both treatment arms
(p<0.001). The proportionof childrenwith moderate (p<0.01) and severe (p<0.02) anaemia changed similarly. Median haemoglobin values and the
proportionof children with moderate or severe anaemia did not differ significantly between treatment groups.
doi:10.1371/journal.pone.0161495.t003
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P. falciparum remain sensitive to artemisinin derivatives. The numbers are small and data
should be interpreted with caution, especially as we do not have data on drug concentrations.
However, AL has previously been linked to an increased risk of persistent parasitaemia on day
one compared to DP [17]. Furthermore, as shown in earlier studies, the frequency of genotypes
associated with five-fold higher lumefantrine IC50 values was high (~75%) when AL was intro-
duced in Guinea-Bissau [13, 18]. The results therefore highlight the importance of continued
AL efficacymonitoring in Guinea-Bissau.
Lower incidence of uncomplicated and complicated malaria infections, fewer hospitaliza-
tions, better haemoglobin values and lower risk of developing gametocytaemiahave been
found in children treated with DP compared to AL [8, 9, 19]. These effects have been attributed
to a post treatment prophylactic effect due to the longer terminal elimination half-life of piper-
aquine compared to lumefantrine. In our study DP was no better than AL at preventing rein-
fections and haemoglobin values did not differ between treatment groups. This was no doubt
due to the currently low transmission intensity (there were only two reinfections) at our site in
line with data from a meso-endemic area of Kenya [20]. When malaria resurged in Bissau
(2008–2012), reinfections were common even during the short seasonal transmission period. A
drug with a long post treatment prophylactic effectmight limit onward transmission of malaria
during epidemics. Based on previous data and the high efficacy of DP in this study it is possible
that use of DP can minimise seasonal peaks of malaria in Guinea-Bissau.
Both drugs were well tolerated and fever clearance, symptom resolution and haemoglobin
recovery were similar. DP has previously been linked to increased risk of vomiting in infants
[21] and we found that the need to repeat treatment due to vomiting was non-significantly
more common after the first dose of DP (n = 7) compared to AL (n = 4). However, vomiting
was not seen with subsequent doses and no child was withdrawn due to vomiting indicating
that both treatments were well tolerated.
As expected haemoglobin values were lower on day 3 than day 0. The day 3 haemoglobin
value was also less likely to be effected by fever and dehydration as the clinical condition of the
vast majority of children was assessed as good on day 3. Thus the increase of haemoglobin
between days 3 and 42 is most probably a more accurate reflection of haemoglobin recovery
than the day 0 and day 42 comparison commonly used.
Conclusions
Both AL and DP fulfilledWHO criteria for treatment of uncomplicated P. falciparum malaria
and can be recommended for use in Guinea-Bissau. DP was not inferior to AL for treatment of
uncomplicated P. falciparum malaria. Haemoglobin recovery is better assessed by measuring
haemoglobin on days 3 and 42 compared to days 0 and 42.
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